Drugs / Anti-coronavirus antibodies
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04418531 | Jun 2020 → Sep 2022 | COVID-19, viral pneumonia | Piero Luigi Ruggenenti | Withdrawn | No outcome recorded |
| — | NCT04346589 | Apr 2020 → Feb 2021 | COVID-19 | A.O. Ospedale Papa Giovanni XXIII | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-03-09 | Grifols Therapeutics LLC | Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins grifols.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-coronavirus antibodies | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04418531 ↗ |
| Known as | immunoglobulins | “Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients” NCT04346589 ↗ |
| Modality | Protein / enzyme biologic | “Anti-coronavirus antibodies (immunoglobulins)” NCT04418531 ↗ |